Research ArticlePharmacology Vignette
Natalizumab (Tysabri)
D.T. Selewski, G.V. Shah, B.M. Segal, P.A. Rajdev and S.K. Mukherji
American Journal of Neuroradiology October 2010, 31 (9) 1588-1590; DOI: https://doi.org/10.3174/ajnr.A2226
D.T. Selewski
G.V. Shah
B.M. Segal
P.A. Rajdev

References
- 1.↵
- Rudick RA,
- Stuart WH,
- Calabresi PA,
- et al
- 2.↵
- Polman CH,
- O'Connor PW,
- Havrdova,
- et al
- 3.↵
- 4.↵
- Ghosh S,
- Goldin E,
- Gordon FH,
- et al
- 5.↵
- Sandborn WJ,
- Colombel JF,
- Enns R,
- et al
- 6.↵
Department of Health and Human Services. Tysabri risk minimization action plan: summary of TOUCH. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM107197.pdf. Accessed June 28, 2010
- 7.↵
- Lobb RR,
- Hemler ME
- 8.↵
- 9.↵
- Brocke S,
- Piercy C,
- Steinman L,
- et al
- 10.↵
- Rice GP,
- Hartung HP,
- Calabresi PA
- 11.↵
- Ley K,
- Laudanna C,
- Cybulsky MI,
- et al
- 12.↵
- Goodin DS,
- Cohen BA,
- O'Connor P,
- et al
- 13.↵
- 14.↵
- Miller DH,
- Khan OA,
- Sheremata WA,
- et al
- 15.↵
- Clifford DB,
- DeLuca A,
- Simpson DM,
- et al
- 16.↵
- Bezabeh S,
- Flowers CM,
- Kortepeter C,
- et al
- 17.↵
Center for Drug Evaluation and Research (CDER). Tysabri (Natalizumab) biologic license application 125104/15. In: Proceedings of the Peripheral and Central Nervous System Drugs Advisory Committee, Gaithersburg, Maryland. 3 7–8, 2006; available at http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4208S1-Slide-Index.htm. Accessed June 28, 2010
- 18.↵
- Ismail A,
- Kemp J,
- Sharrack B
- 19.↵
- Mullen JT,
- Vartanian TK,
- Atkins MB
In this issue
Advertisement
Natalizumab (Tysabri)
D.T. Selewski, G.V. Shah, B.M. Segal, P.A. Rajdev, S.K. Mukherji
American Journal of Neuroradiology Oct 2010, 31 (9) 1588-1590; DOI: 10.3174/ajnr.A2226
Related Articles
- No related articles found.
Cited By...
This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.
More in this TOC Section
Similar Articles
Advertisement